{"id":6670,"date":"2024-11-21T14:58:35","date_gmt":"2024-11-21T13:58:35","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6670"},"modified":"2025-04-28T21:56:34","modified_gmt":"2025-04-28T19:56:34","slug":"tislelizumab-vs-sorafenib-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-a-phase-3-randomized-clinical-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-vs-sorafenib-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-a-phase-3-randomized-clinical-trial\/","title":{"rendered":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a Phase 3 randomized clinical trial\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6670","publication","type-publication","status-publish","hentry","disease_state-hepatocellular-carcinoma","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6670"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}